ASCO 2016 | Cabozantinib for advanced renal cell carcinoma: the METEOR and CABOSUN trials
Sumanta Pal, MD of City of Hope, Duarte, CA, discusses the introduction of new data of the new single-agent cabozantinib for advanced renal cell carcinoma. The agent is a dual MET and VEGFR2 inhibitor, and has been assessed in metastatic renal cell carcinoma and other diseases. Dr Pal highlights his involvement in the Phase I trials of cabozantinib’s development in renal cell carcinoma, where impressive responses were observed. He proceeds to highlight that most recently, cabozantinib was used in a Phase III METEOR trial comparing it to the agent everolimus (NCT01865747). This study identified an improvement in response rate, overall survival (OS) and progression-free survival (PFS) for patients with advanced renal cell carcinoma. According to Dr Pal, these findings make the agent the optimal second-line choice in patients with metastatic renal cell carcinoma. He further adds that data from the CABOSUN study (NCT01835158), a clinical trial that compared sunitinib and cabozantinib in the front-line setting, will hopefully be available shortly. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.
Get great new content delivered to your inboxSign up